https://www.selleckchem.com/pr....oducts/l-ornithine-l
17%; P=0.45), and the change of brain natriuretic peptide was non-significantly greater with QSYQ compared with placebo (median change -14.55 vs. -12.30pg/mL, respectively; P=0.21). By contrast, the Minnesota Living with Heart Failure Questionnaire score significantly improved with QSYQ compared with placebo (-11.78 vs. -9.17; P=0.004). Adverse events were minor and infrequent with QSYQ, similar to the placebo group. Treatment with QSYQ for 6months in addition to standard therapy improved exercise tolerance of IHF patien
Me gusta
Comentario
Compartir
